Bart van den Bemt has been appointed professor (by special appointment) of Personalized Pharmaceutical Care at Radboud University/Radboud university medical center with effect from 1 March 2020.
Van den Bemt is a pharmacist, clinical pharmacologist and senior researcher at Radboud university medical center and the Sint Maartenskliniek. His special teaching and research remit was established in collaboration with the Sint Maartenskliniek and comprises two half days a week. Based on a scientific, personal and innovative approach, Van den Bemt aims to make the use of medicine by patients safer, more effective and more efficient. He will pay particular attention to shared decision-making, improved treatment adherence, effective pharmacotherapy and sustainable drug use.
About Bart van den Bemt
Van den Bemt (Breda, 1972) studied Pharmacy at Utrecht University and obtained his pharmacy certificate in 1996, after which he was registered as a Public Pharmacist in 1998. In 2009 he received his PhD from Radboud University on research into the optimisation of pharmacotherapy in patients with rheumatoid arthritis. From 2010-2014 he trained as a clinical pharmacologist at Radboud university medical center.
Prof. Van den Bemt is a member of the scientific advisory board of the Royal Dutch Pharmacists Association (KNMP), president of the European Society of Clinical Pharmacy (ESCP), chair of the committee on scientific affairs and research of the Dutch association of hospital pharmacists (NVZA) and chair of the Centrum for Patiënt en Geneesmiddel foundation.
Related news items
The patient's need for medication information and its perceived quality3 September 2020
In the International Journal of Clinical Pharmacy Charlotte Bekker showed that patients often face unmet medication information needs and that the quality of the provided information, including accessibility, comprehensiveness, reliability and understandability, is perceived as insufficient.read more
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
The PRIDE Study Evaluation of online methods of data collection16 January 2020
In Paediatric and Perinatal Epidemiology RIHS researchers Marleen van Gelder and Nel Roeleveld described the recruitment methods and online data collection within the PRIDE Study, the largest Dutch birth cohort study.read more
Association of gestational weight gain with adverse maternal and infant outcomes13 May 2019
An individual participant meta-analysis published in JAMA showed that pregnancy BMI is related stronger to maternal and infant complications than to gestational weight gain. The PRIDE Study, with coauthors Marleen van Gelder and Nel Roeleveld, was one of the participating cohorts.read more